Taguchi T
Hospital Attached to Research Institute for Microbial Diseases, Osaka University.
Gan To Kagaku Ryoho. 1991 May;18(6):945-51.
We have made over view of new chemotherapeutic regimen for treatment of advanced gastric cancer 5-FU + MMC, FT + MMC and UFT + MMC therapy have been used widely for treatment of advanced gastric cancer as chemotherapeutic regimens in Japan. These regimens did not shown made than 25% in response rate as antitumor effect. Since development of CDDP, FP (5-FU + CDDP), FAP (5-FU + ADM + CDDP) and EAP (Etoposide + ADM + CDDP) is becoming gradually very important regimen for treatment of advanced stomach cancer patients. Recently, we have studied EAP therapy on 50 cases of advanced gastric cancer from January 1988 to September 1989. ADM 20 mg/m2, CDDP 40 mg/m2 and Etoposide 100 mg/m2 were administered on day 1 and 7, 2 and 8, and 4, 5 and 6, respectively, with not less than 2 courses every 3 to 4 weeks. The rate of effectiveness were obtained 43.8% with a confidence interval 95% of 30-58%. Median survival time was only 5.1 months for EAP therapy, which was highly effective but led to no prolonged survival period. Thus it is thought that good control of leukopenia, a dose-limiting factor remains to be examined. Biochemical modulation of 5-FU using such as MTX + LV and CDDP + LV (leucovorin) now under studying in the nation wide in Japan, so far it is getting better results.
我们对晚期胃癌的新化疗方案进行了综述。在日本,5-氟尿嘧啶(5-FU)+丝裂霉素(MMC)、替加氟(FT)+MMC和优福定(UFT)+MMC疗法作为化疗方案已被广泛用于晚期胃癌的治疗。这些方案作为抗肿瘤效果,有效率未显示超过25%。自从顺铂(CDDP)出现以来,氟尿嘧啶+顺铂(FP)、氟尿嘧啶+多柔比星+顺铂(FAP)和依托泊苷+多柔比星+顺铂(EAP)逐渐成为治疗晚期胃癌患者的非常重要的方案。最近,我们在1988年1月至1989年9月期间对50例晚期胃癌患者进行了EAP疗法研究。多柔比星20mg/m²、顺铂40mg/m²和依托泊苷100mg/m²分别在第1天和第7天、第2天和第8天、第4天、第5天和第6天给药,每3至4周不少于2个疗程。有效率为43.8%,95%置信区间为30%-58%。EAP疗法的中位生存时间仅为5.1个月,该疗法虽高效但未延长生存期。因此,认为作为剂量限制因素的白细胞减少的良好控制仍有待研究。目前日本正在全国范围内研究使用甲氨蝶呤(MTX)+亚叶酸钙(LV)和顺铂+LV对5-氟尿嘧啶进行生化调节,到目前为止取得了较好的结果。